{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T05:20:26Z","timestamp":1764912026519,"version":"3.46.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the grants from National Natural Sciences Foundation of China","award":["82274022"],"award-info":[{"award-number":["82274022"]}]},{"name":"the third session of the support programs for topnotch talents, Jiangsu Provincial People\u2019s Hospital, China","award":["YNRCQN025"],"award-info":[{"award-number":["YNRCQN025"]}]},{"name":"Jiangsu Pharmaceutical Association-Aosaikang Pharmaceutical Co.Ltd Hospital Pharmacy Research Key Project","award":["A202204"],"award-info":[{"award-number":["A202204"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00228-025-03922-7","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T11:55:15Z","timestamp":1759751715000},"page":"1853-1864","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Influence of genetic variants of imatinib on pharmacokinetics and recurrence-free survival in postoperative patients with gastrointestinal stromal tumor"],"prefix":"10.1007","volume":"81","author":[{"given":"Luning","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiongye","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianghao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"issue":"9896","key":"3922_CR1","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S0140-6736(13)60106-3","volume":"382","author":"H Joensuu","year":"2013","unstructured":"Joensuu H, Hohenberger P, Corless CL (2013) Gastrointestinal stromal tumour. Lancet (London, England) 382(9896):973\u2013983. https:\/\/doi.org\/10.1016\/S0140-6736(13)60106-3","journal-title":"Lancet (London, England)"},{"issue":"1","key":"3922_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/bjc.2017.144","volume":"117","author":"Y Kurokawa","year":"2017","unstructured":"Kurokawa Y, Yang HK, Cho H et al (2017) Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. Br J Cancer 117(1):25\u201332. https:\/\/doi.org\/10.1038\/bjc.2017.144","journal-title":"Br J Cancer"},{"issue":"1","key":"3922_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00254-5","volume":"7","author":"JY Blay","year":"2021","unstructured":"Blay JY, Kang YK, Nishida T, Von Mehren M (2021) Gastrointestinal stromal tumours. Nat Rev Dis Primers 7(1):22. https:\/\/doi.org\/10.1038\/s41572-021-00254-5","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"3922_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01026-6","volume":"14","author":"CM Kelly","year":"2021","unstructured":"Kelly CM, Gutierrez Sainz L, Chi P (2021) The management of metastatic GIST: current standard and investigational therapeutics. J Hematol Oncol 14(1):2. https:\/\/doi.org\/10.1186\/s13045-020-01026-6","journal-title":"J Hematol Oncol"},{"issue":"7","key":"3922_CR5","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, Von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472\u2013480. https:\/\/doi.org\/10.1056\/NEJMoa020461","journal-title":"N Engl J Med"},{"key":"3922_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejca.2015.12.029","volume":"57","author":"S Bouchet","year":"2016","unstructured":"Bouchet S, Poulette S, Titier K et al (2016) Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting. Eur J Cancer 57:31\u201338. https:\/\/doi.org\/10.1016\/j.ejca.2015.12.029. (Oxford, England\u202f: 1990)","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"issue":"4","key":"3922_CR7","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1200\/JCO.2007.13.4403","volume":"26","author":"CD Blanke","year":"2008","unstructured":"Blanke CD, Demetri GD, Von Mehren M et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26(4):620\u2013625. https:\/\/doi.org\/10.1200\/JCO.2007.13.4403","journal-title":"J Clin Oncol"},{"issue":"19","key":"3922_CR8","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1200\/JCO.2008.20.4818","volume":"27","author":"GD Demetri","year":"2009","unstructured":"Demetri GD, Wang Y, Wehrle E et al (2009) Imatinib plasma levels are correlated with clinical benefit in patients with unresectable\/metastatic gastrointestinal stromal tumors. J Clin Oncol 27(19):3141\u20133147. https:\/\/doi.org\/10.1200\/JCO.2008.20.4818","journal-title":"J Clin Oncol"},{"key":"3922_CR9","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2147\/DDDT.S400986","volume":"17","author":"X Jiang","year":"2023","unstructured":"Jiang X, Fu Q, Jing Y et al (2023) Personalized dose of adjuvant imatinib in patients with gastrointestinal stromal tumors: results from a population pharmacokinetic analysis. Drug Des Devel Ther 17:809\u2013820. https:\/\/doi.org\/10.2147\/DDDT.S400986","journal-title":"Drug Des Devel Ther"},{"issue":"12","key":"3922_CR10","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.annonc.2024.08.2343","volume":"35","author":"JY Blay","year":"2024","unstructured":"Blay JY, Schiffler C, Bouch\u00e9 O et al (2024) A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse. Ann Oncol Off J Eur Soc Medical Oncology 35(12):1157\u20131168. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2343","journal-title":"Ann Oncol Off J Eur Soc Medical Oncology"},{"issue":"20","key":"3922_CR11","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.1158\/1078-0432.CCR-12-0490","volume":"18","author":"K Eechoute","year":"2012","unstructured":"Eechoute K, Fransson MN, Reyners AK et al (2012) A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res 18(20):5780\u20135787. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0490","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3922_CR12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40262-016-0439-7","volume":"56","author":"S Farag","year":"2017","unstructured":"Farag S, Verheijen RB, Martijn Kerst J et al (2017) Imatinib pharmacokinetics in a large observational cohort of gastrointestinal stromal tumour patients. Clin Pharmacokinet 56(3):287\u2013292. https:\/\/doi.org\/10.1007\/s40262-016-0439-7","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"3922_CR13","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s10147-023-02325-x","volume":"28","author":"R Teranishi","year":"2023","unstructured":"Teranishi R, Takahashi T, Nishida T et al (2023) Plasma trough concentration of imatinib and its effect on therapeutic efficacy and adverse events in Japanese patients with GIST. Int J Clin Oncol 28(5):680\u2013687. https:\/\/doi.org\/10.1007\/s10147-023-02325-x","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"3922_CR14","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s10637-011-9633-5","volume":"30","author":"C Yoo","year":"2012","unstructured":"Yoo C, Ryu MH, Ryoo BY et al (2012) Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure. Invest New Drugs 30(4):1703\u20131708. https:\/\/doi.org\/10.1007\/s10637-011-9633-5","journal-title":"Invest New Drugs"},{"issue":"3","key":"3922_CR15","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/FTD.0000000000000004","volume":"36","author":"NA Lankheet","year":"2014","unstructured":"Lankheet NA, Knapen LM, Schellens JH et al (2014) Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care. Ther Drug Monit 36(3):326\u2013334. https:\/\/doi.org\/10.1097\/FTD.0000000000000004","journal-title":"Ther Drug Monit"},{"key":"3922_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.569843","volume":"11","author":"Y Chen","year":"2020","unstructured":"Chen Y, Dong X, Wang Q et al (2020) Factors influencing the steady-state plasma concentration of imatinib mesylate in patients with gastrointestinal stromal tumors and chronic myeloid leukemia. Front Pharmacol 11:569843. https:\/\/doi.org\/10.3389\/fphar.2020.569843","journal-title":"Front Pharmacol"},{"issue":"8","key":"3922_CR17","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G et al (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109(8):3496\u20133499. https:\/\/doi.org\/10.1182\/blood-2006-07-036012","journal-title":"Blood"},{"issue":"Suppl 9","key":"3922_CR18","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1002\/cncr.32751","volume":"126","author":"Y Xia","year":"2020","unstructured":"Xia Y, Chen S, Luo M et al (2020) Correlations between imatinib plasma trough concentration and adverse reactions in Chinese patients with gastrointestinal stromal tumors. Cancer 126(Suppl 9):2054\u20132061. https:\/\/doi.org\/10.1002\/cncr.32751","journal-title":"Cancer"},{"issue":"22","key":"3922_CR19","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1002\/cncr.34478","volume":"128","author":"F Cheng","year":"2022","unstructured":"Cheng F, Zeng F, Li Q et al (2022) Imatinib dose optimization based on therapeutic drug monitoring in Chinese patients with chronic-phase chronic myeloid leukemia. Cancer 128(22):3951\u20133958. https:\/\/doi.org\/10.1002\/cncr.34478","journal-title":"Cancer"},{"issue":"3","key":"3922_CR20","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1093\/annonc\/mds532","volume":"24","author":"SJ Seong","year":"2013","unstructured":"Seong SJ, Lim M, Sohn SK et al (2013) Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients. Ann Oncol 24(3):756\u2013760. https:\/\/doi.org\/10.1093\/annonc\/mds532","journal-title":"Ann Oncol"},{"issue":"3","key":"3922_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18030603","volume":"18","author":"J Liu","year":"2017","unstructured":"Liu J, Chen Z, Chen H et al (2017) Genetic polymorphisms contribute to the individual variations of imatinib mesylate plasma levels and adverse reactions in Chinese GIST patients. Int J Mol Sci 18(3):603. https:\/\/doi.org\/10.3390\/ijms18030603","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3922_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043303","volume":"24","author":"C Dalle Fratte","year":"2023","unstructured":"Dalle Fratte C, Polesel J, Gagno S et al (2023) Impact of ABCG2 and ABCB1 polymorphisms on imatinib plasmatic exposure: an original work and meta-analysis. Int J Mol Sci 24(4):3303. https:\/\/doi.org\/10.3390\/ijms24043303","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3922_CR23","doi-asserted-by":"publisher","first-page":"577","DOI":"10.21037\/jgo-24-188","volume":"15","author":"Y Ge","year":"2024","unstructured":"Ge Y, Bai H, Mazzocca A et al (2024) Contribution of genetic polymorphism in ABCB1 to individual variations of imatinib plasma levels in patients with gastrointestinal stromal tumor. J Gastrointest Oncol 15(2):577\u2013584. https:\/\/doi.org\/10.21037\/jgo-24-188","journal-title":"J Gastrointest Oncol"},{"key":"3922_CR24","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ejca.2021.08.033","volume":"157","author":"WA Clarke","year":"2021","unstructured":"Clarke WA, Chatelut E, Fotoohi AK et al (2021) Therapeutic drug monitoring in oncology: International association of therapeutic drug monitoring and clinical toxicology consensus guidelines for imatinib therapy. Eur J Cancer 157:428\u2013440. https:\/\/doi.org\/10.1016\/j.ejca.2021.08.033","journal-title":"Eur J Cancer"},{"key":"3922_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231192388","volume":"15","author":"C Serrano","year":"2023","unstructured":"Serrano C, Mart\u00edn-Broto J, Asencio-Pascual JM et al (2023) 2023 GEIS guidelines for gastrointestinal stromal tumors. Ther Adv Med Oncol 15:17588359231192388. https:\/\/doi.org\/10.1177\/17588359231192388","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"3922_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ctrv.2010.10.001","volume":"37","author":"M Von Mehren","year":"2011","unstructured":"Von Mehren M, Widmer N (2011) Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer Treat Rev 37(4):291\u2013299. https:\/\/doi.org\/10.1016\/j.ctrv.2010.10.001","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"3922_CR27","doi-asserted-by":"publisher","first-page":"695","DOI":"10.6004\/jnccn.2024.0061","volume":"22","author":"R Hodan","year":"2024","unstructured":"Hodan R, Gupta S, Weiss JM et al (2024) Genetic\/familial high-risk assessment: colorectal, endometrial, and gastric, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 22(10):695\u2013711. https:\/\/doi.org\/10.6004\/jnccn.2024.0061","journal-title":"J Natl Compr Canc Netw"},{"key":"3922_CR28","unstructured":"Wei XH, Luan JJ, Li GH (2024) Consensus of Chinese experts on individualized medication management of imatinib for gastrointestinal stromal tumors. China Pharm 35(3):257\u2013270. Translated by Xu, M. Q. This guideline is developed by a group of renowned experts in [field] in China and is widely recognized in the domestic industry"},{"issue":"1","key":"3922_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/sj.clpt.6100201","volume":"82","author":"H Gurney","year":"2007","unstructured":"Gurney H, Wong M, Balleine RL et al (2007) Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther 82(1):33\u201340. https:\/\/doi.org\/10.1038\/sj.clpt.6100201","journal-title":"Clin Pharmacol Ther"},{"issue":"14","key":"3922_CR30","doi-asserted-by":"publisher","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-09-0145","volume":"15","author":"DH Kim","year":"2009","unstructured":"Kim DH, Sriharsha L, Xu W et al (2009) Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 15(14):4750\u20134758. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0145","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3922_CR31","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ctrv.2010.08.006","volume":"37","author":"HJ Kl\u00fcmpen","year":"2011","unstructured":"Kl\u00fcmpen HJ, Samer CF, Mathijssen RH et al (2011) Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev 37(4):251\u2013260. https:\/\/doi.org\/10.1016\/j.ctrv.2010.08.006","journal-title":"Cancer Treat Rev"},{"issue":"17","key":"3922_CR32","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2217\/pgs-2016-0124","volume":"17","author":"S Chen","year":"2016","unstructured":"Chen S, Sutiman N, Chowbay B (2016) Pharmacogenetics of drug transporters in modulating imatinib disposition and treatment outcomes in chronic myeloid leukemia & gastrointestinal stromal tumor patients. Pharmacogenomics 17(17):1941\u20131955. https:\/\/doi.org\/10.2217\/pgs-2016-0124","journal-title":"Pharmacogenomics"},{"issue":"2","key":"3922_CR33","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00280-022-04454-y","volume":"90","author":"YH Chien","year":"2022","unstructured":"Chien YH, W\u00fcrthwein G, Zubiaur P et al (2022) Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400 mg. Cancer Chemother Pharmacol 90(2):125\u2013136. https:\/\/doi.org\/10.1007\/s00280-022-04454-y","journal-title":"Cancer Chemother Pharmacol"},{"key":"3922_CR34","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.bcp.2017.12.015","volume":"153","author":"Y Uno","year":"2018","unstructured":"Uno Y, Uehara S, Yamazaki H (2018) Genetic polymorphisms of drug-metabolizing cytochrome P450 enzymes in cynomolgus and rhesus monkeys and common marmosets in preclinical studies for humans. Biochem Pharmacol 153:184\u2013195. https:\/\/doi.org\/10.1016\/j.bcp.2017.12.015","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"3922_CR35","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","volume":"44","author":"B Peng","year":"2005","unstructured":"Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44(9):879\u2013894. https:\/\/doi.org\/10.2165\/00003088-200544090-00001","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"3922_CR36","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/j.1476-5381.2010.00946.x","volume":"161","author":"N Nebot","year":"2010","unstructured":"Nebot N, Crettol S, d\u2019Esposito F et al (2010) Participation of CYP2C8 and CYP3A4 in the n-demethylation of imatinib in human hepatic microsomes. Br J Pharmacol 161(5):1059\u20131069. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00946.x","journal-title":"Br J Pharmacol"},{"issue":"8","key":"3922_CR37","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1111\/j.1476-5381.2011.01732.x","volume":"165","author":"AM Filppula","year":"2012","unstructured":"Filppula AM, Laitila J, Neuvonen PJ et al (2012) Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol 165(8):2787\u20132798. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01732.x","journal-title":"Br J Pharmacol"},{"issue":"1","key":"3922_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-024-04723-y","volume":"95","author":"SA Mangoura","year":"2024","unstructured":"Mangoura SA, Abdel-Raheem MH, Eltyb HA et al (2024) Influence of CYP2C8*3 and ABCG2 C421A genetic polymorphisms on trough concentration and molecular response of imatinib in Egyptian patients with chronic myeloid leukemia. Cancer Chemother Pharmacol 95(1):12. https:\/\/doi.org\/10.1007\/s00280-024-04723-y","journal-title":"Cancer Chemother Pharmacol"},{"issue":"21\u201322","key":"3922_CR39","doi-asserted-by":"publisher","first-page":"6887","DOI":"10.1007\/s00018-021-03901-y","volume":"78","author":"S Kukal","year":"2021","unstructured":"Kukal S, Guin D, Rawat C et al (2021) Multidrug efflux transporter ABCG2: expression and regulation. Cell Mol Life Sci 78(21\u201322):6887\u20136939. https:\/\/doi.org\/10.1007\/s00018-021-03901-y","journal-title":"Cell Mol Life Sci"},{"issue":"13","key":"3922_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310539","volume":"24","author":"A Sa\u0142agacka-Kubiak","year":"2023","unstructured":"Sa\u0142agacka-Kubiak A, Zawada D, Saed L et al (2023) ABCG2 gene and ABCG2 protein expression in colorectal cancer-in silico and wet analysis. Int J Mol Sci 24(13):10539. https:\/\/doi.org\/10.3390\/ijms241310539","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3922_CR41","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1182\/blood-2005-10-4020","volume":"108","author":"T Nakanishi","year":"2006","unstructured":"Nakanishi T, Shiozawa K, Hassel BA et al (2006) Complex interaction of BCRP\/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood 108(2):678\u2013684. https:\/\/doi.org\/10.1182\/blood-2005-10-4020","journal-title":"Blood"},{"key":"3922_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.658039","volume":"12","author":"JW Park","year":"2021","unstructured":"Park JW, Chung H, Kim KA et al (2021) ABCG2 single nucleotide polymorphism affects imatinib pharmacokinetics in lower alpha-1-acid glycoprotein levels in humans. Front Pharmacol 12:658039. https:\/\/doi.org\/10.3389\/fphar.2021.658039","journal-title":"Front Pharmacol"},{"key":"3922_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112090","volume":"133","author":"F Cheng","year":"2024","unstructured":"Cheng F, Cui Z, Li Q et al (2024) Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia. Int Immunopharmacol 133:112090. https:\/\/doi.org\/10.1016\/j.intimp.2024.112090","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"3922_CR44","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","volume":"110","author":"DL White","year":"2007","unstructured":"White DL, Saunders VA, Dang P et al (2007) Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110(12):4064\u20134072. https:\/\/doi.org\/10.1182\/blood-2007-06-093617","journal-title":"Blood"},{"issue":"4","key":"3922_CR45","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/ejh.12235","volume":"92","author":"M Koren-Michowitz","year":"2014","unstructured":"Koren-Michowitz M, Buzaglo Z, Ribakovsky E et al (2014) OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients. Eur J Haematol 92(4):283\u2013288. https:\/\/doi.org\/10.1111\/ejh.12235","journal-title":"Eur J Haematol"},{"issue":"4","key":"3922_CR46","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000336244","volume":"127","author":"JS Zhong","year":"2012","unstructured":"Zhong JS, Meng FY, Xu D et al (2012) Correlation between imatinib trough concentration and efficacy in Chinese chronic myelocytic leukemia patients. Acta Haematol 127(4):221\u2013227. https:\/\/doi.org\/10.1159\/000336244","journal-title":"Acta Haematol"},{"issue":"2","key":"3922_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020914","volume":"23","author":"L Pochini","year":"2022","unstructured":"Pochini L, Galluccio M, Scalise M et al (2022) OCTN1: a widely studied but still enigmatic organic cation transporter linked to human pathology and drug interactions. Int J Mol Sci 23(2):914. https:\/\/doi.org\/10.3390\/ijms23020914","journal-title":"Int J Mol Sci"},{"issue":"8","key":"3922_CR48","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1080\/14728222.2018.1502273","volume":"22","author":"L Kou","year":"2018","unstructured":"Kou L, Sun R, Ganapathy V et al (2018) Recent advances in drug delivery via the organic cation\/carnitine transporter 2 (OCTN2\/SLC22A5). Expert Opin Ther Targets 22(8):715\u2013726. https:\/\/doi.org\/10.1080\/14728222.2018.1502273","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"3922_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25010014","volume":"25","author":"B Juraszek","year":"2019","unstructured":"Juraszek B, Na\u0142\u0119cz KA (2019) SLC22A5 (OCTN2) carnitine transporter-indispensable for cell metabolism, a Jekyll and Hyde of human cancer. Molecules 25(1):14. https:\/\/doi.org\/10.3390\/molecules25010014","journal-title":"Molecules"},{"issue":"2","key":"3922_CR50","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ajps.2020.02.002","volume":"15","author":"G Wang","year":"2020","unstructured":"Wang G, Zhao L, Jiang Q et al (2020) Intestinal OCTN2- and MCT1-targeted drug delivery to improve oral bioavailability. Asian J Pharm Sci 15(2):158\u2013173. https:\/\/doi.org\/10.1016\/j.ajps.2020.02.002","journal-title":"Asian J Pharm Sci"},{"issue":"12","key":"3922_CR51","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1158\/1535-7163.MCT-18-0498","volume":"17","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Xu J, Qian Y et al (2018) Association of imatinib plasma concentration and single-nucleotide polymorphisms with adverse drug reactions in patients with gastrointestinal stromal tumors. Mol Cancer Ther 17(12):2780\u20132787. https:\/\/doi.org\/10.1158\/1535-7163.MCT-18-0498","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"3922_CR52","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41375-023-02109-2","volume":"38","author":"K Machova Polakova","year":"2024","unstructured":"Machova Polakova K, Albeer A, Polivkova V et al (2024) The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib. Leukemia 38(2):318\u2013325. https:\/\/doi.org\/10.1038\/s41375-023-02109-2","journal-title":"Leukemia"},{"issue":"1","key":"3922_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2012.10.015","volume":"68","author":"S Angelini","year":"2013","unstructured":"Angelini S, Pantaleo MA, Ravegnini G et al (2013) Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy. Pharmacol Res 68(1):1\u20136. https:\/\/doi.org\/10.1016\/j.phrs.2012.10.015","journal-title":"Pharmacol Res"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03922-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03922-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03922-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T04:43:47Z","timestamp":1764909827000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03922-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":53,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3922"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03922-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}